Trial Profile
A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Larotrectinib (Primary)
- Indications Carcinoma; CNS cancer; Glioma; Meningeal carcinomatosis; Neuroblastoma; Neuroepithelial neoplasms; Sarcoma; Solid tumours; Thyroid cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SCOUT
- Sponsors Bayer; Loxo Oncology
- 24 Oct 2023 Results of a pooled analysis from three clinical studies: NCT02576431, NCT02122913, NCT02637687 ; assessing updated efficacy and safety data in an expanded dataset of patients with longer follow-up presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Results of an efficacy analysis from three clinical studies (NCT02576431, NCT02122913, NCT02637687) including treatment-naive non-primary CNS TRK fusion cancer patients from these trials presented at the 48th European Society for Medical Oncology Congress
- 28 Sep 2023 Results of subset analysis (As of data cutoff was July 20, 2021 from three clinical trials NCT02122913 and NCT02576431 (NAVIGATE), including this trial) evaluating the efficacy and safety of larotrectinib in an expanded data set of adult patients with TRK fusion sarcomas with longer follow-up, published in the Cancer.